ACP-103, a 5-HT2A receptor inverse agonist.
Copyright policy )ACP-103, a 5-HT2A receptor inverse agonist.
ACADIA Pharmaceuticals is developing ACP-103, lead compound in a series of 5-HT2A inverse agonists, as a potential antipsychotic agent and for the potential treatment of insomnia. Phase II clinical trials in treatment-induced psychosis in Parkinson's disease (PD) patients and in schizophrenic patients are ongoing, as are phase II trials evaluating the effects of the drug on PD symptoms and dyskinesias.
- GlaxoSmithKline (United Kingdom) United Kingdom
Structure-Activity Relationship, Clinical Trials, Phase II as Topic, Clinical Trials, Phase I as Topic, Piperidines, Contraindications, Animals, Humans, Urea, Receptor, Serotonin, 5-HT2A, Serotonin Receptor Agonists
Structure-Activity Relationship, Clinical Trials, Phase II as Topic, Clinical Trials, Phase I as Topic, Piperidines, Contraindications, Animals, Humans, Urea, Receptor, Serotonin, 5-HT2A, Serotonin Receptor Agonists
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).30 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!